Key Highlights

  • Tradr 2X Long Tempus AI ETF (Nasdaq: TEMT) rose 10.80%, amplified by gains in Tempus AI (NASDAQ: TEM), its underlying leveraged exposure.
  • TD Cowen raised its price target on Tempus AI (NASDAQ: TEM) to $68 from $65 while maintaining a Buy rating.
  • Tempus AI (NASDAQ: TEM) reported first-quarter Revenue of $348.1 million, up 36.1% year over year and ahead of consensus expectations.
  • The company launched Tempus Preview, an AI-based oncology tool designed to provide early biomarker insights within about 24 hours of tissue receipt.
  • Despite strong sales growth, Tempus AI (NASDAQ: TEM) remains unprofitable, with weak quarterly Cash Flow and a significant EBITDA loss over the last twelve months.

Why TEMT ETF Is Rising Today

Tradr 2X Long Tempus AI ETF (NASDAQ: TEMT) is rising 10.80% as investors respond to improving sentiment around Tempus AI (NASDAQ: TEM), a healthcare technology company focused on applying artificial intelligence to precision medicine.

Because Tradr 2X Long Tempus AI ETF (NASDAQ: TEMT) is designed to provide leveraged exposure to Tempus AI (NASDAQ: TEM), daily moves in the underlying stock can be magnified. That structure can produce sharp gains when the stock rises, but it also increases downside risk when sentiment reverses.

The immediate catalyst was a more constructive analyst view. TD Cowen lifted its price target on Tempus AI (NASDAQ: TEM) to $68 from $65 while maintaining a Buy rating. The revised target sits within a wide broader analyst range of $35 to $100, reflecting both enthusiasm for the company’s growth profile and uncertainty around valuation, profitability and execution.

Tempus AI Revenue Growth Supports Healthcare AI Narrative

Tempus AI (NASDAQ: TEM) delivered first-quarter revenue of $348.1 million, up 36.1% from $255.7 million a year earlier and ahead of analyst expectations of $345.4 million. The company’s adjusted loss of $0.13 per share was also narrower than the expected loss of $0.20 per share.

The revenue performance was supported by strength across genomics and data operations. TD Cowen noted that data Business-to-business revenue exceeded expectations, an important signal for investors tracking the monetisation of Tempus AI’s (NASDAQ: TEM) clinical and molecular data Assets.

Over the last twelve months, revenue rose 83% to $1.27 billion, while Margin/">Gross Profit Margin stood at 63%. Those figures underscore the company’s scale advantage in a market where healthcare data, diagnostics and AI-driven workflow tools are increasingly converging.

Still, the Earnings profile remains uneven. Tempus AI (NASDAQ: TEM) reported a GAAP loss of $0.70 per share, weaker than expected, and the company recorded an EBITDA loss of $171.5 million over the last twelve months. Cash flow was also weak during the quarter, although TD Cowen cited seasonality as a contributing Factor.

Tempus Preview Adds AI Oncology Product Catalyst

Investor interest was also supported by the launch of Tempus Preview, an application designed to provide early, clinically significant oncology insights before final sequencing results are delivered.

The product aims to close a key timing gap in cancer diagnostics. In many oncology cases, clinicians must make initial treatment decisions while waiting for comprehensive genomic profiling. Tempus Preview uses AI to surface preliminary biomarker predictions within about 24 hours of tissue receipt.

At launch, the application focuses on high-impact cancer biomarkers, including MSI-H status in colorectal, endometrial, prostate and esophagogastric cancers; EGFR mutation prediction in non-small cell lung cancer; and potential FGFR fusions in hepatobiliary and bladder cancers.

The predictions are powered by Paige Predict, an AI model trained on millions of slides and validated for clinical use as part of Tempus AI’s (NASDAQ: TEM) laboratory-developed test. For investors, the launch strengthens the company’s positioning at the intersection of diagnostics, real-world data and clinical decision support.

Risks Remain Around Profitability, Cash Flow and Valuation

The rally in Tradr 2X Long Tempus AI ETF (NASDAQ: TEMT) reflects optimism around growth, product innovation and analyst support. However, the underlying business still faces material financial risks.

Tempus AI (NASDAQ: TEM) is not expected to be profitable this year, and its current valuation remains sensitive to execution against revenue growth, margin improvement and cash flow targets. Ambry performance also fell short of TD Cowen’s estimates, though the firm expects improvement over time.

For Tradr 2X Long Tempus AI ETF (NASDAQ: TEMT), these risks are amplified by Leverage. The ETF’s daily performance is tied to the underlying movement in Tempus AI (NASDAQ: TEM), making it more volatile than direct exposure to the stock.

The latest move therefore reflects a combination of analyst confidence, strong top-line growth and product momentum in healthcare AI. It does not remove the central question for investors: whether Tempus AI (NASDAQ: TEM) can convert rapid revenue expansion and clinical data scale into durable profitability and positive free cash flow.